A phase III, randomized, controlled study of mFOLFOX6 + bevacizumab combination therapy versus mFOLFOX6 + panitumumab combination therapy in chemotherapy-naive patients with KRAS/NRAS wild-type, incurable/unresectable, advanced/recurrent colorectal cancer
Ontology highlight
ABSTRACT: Interventions: mFOLFOX6 + panitumumab
mFOLFOX6 + bevacizumab
Primary outcome(s): 1. Overall survival (OS) 2. OS for Participants with Left-sided Tumors
Study Design: Parallel Randomized
DISEASE(S): Colorectal Cancer
PROVIDER: 2632097 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA